Silence Therapeutics
 | This article contains promotional content. (January 2022) |
 | |
| Company type | Public (Nasdaq: SLN) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1994 |
| Headquarters | Hammersmith, London |
Number of employees | 120 |
| Website | www.silence-therapeutics.com |
Silence Therapeutics (Nasdaq: SLN[1]) is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.[2]
Development
[edit]Silence Therapeutics develops medicines related to RNA interference or RNAi to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet needs. Silence's mRNA GOLD platform can be used to create siRNAs (short interfering RNAs) that target and silence disease-associated genes in the liver.[citation needed]
Silence Therapeutic's product candidates include SLN124 for hematological diseases[citation needed] and zerlasiran (formerly SLN360) for reducing cardiovascular risk in people born with high levels of lipoprotein(a),[citation needed] a genetic risk factor for cardiovascular disease. The company reported in November 2023 that a phase 1 study showed injection of repeated doses reduced patients' baseline of Lp(a) by up to 99 per cent for 90 days after.[3]
Partnerships
[edit]Silence Therapeutics is under the stewardship of CEO Craig Tooman, and has established partnerships with pharmaceutical companies, such as AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others.[4]
References
[edit]- ^ "Google Finance Stock Exchange listing for Silence Therapeutics".
- ^ "About us". silence-therapeutics.com. Archived from the original on 26 March 2023. Retrieved 26 June 2023.
- ^ "Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease". DAIC. 10 November 2023. Retrieved 23 August 2024.
- ^ "Transcript : Silence Therapeutics plc Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 09". MarketScreener. 12 January 2023. Retrieved 23 August 2024.
